Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

Europe

Siemens ordered to recall mammography device across European countries

11 June 2026 The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.

Careers

MoFo bags IP trial duo with 50 years’ combined experience

11 June 2026 The opportunity to grow a “powerhouse IP litigation practice in the heart of New York” was behind the lateral move of highly experienced litigators to Morrison Foerster.

More features

Moderna: BioNTech is claiming work ‘it never did’

Siemens ordered to recall mammography device across European countries

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features